The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma

Two randomised controlled trials (n=312, n=22) showed statistically significant improvement in asthma‑related quality of life in people with severe persistent allergic asthma when Airsonett was compared with a placebo device.

There was no statistically significant difference in asthma medication usage or exacerbation rates, which were secondary outcome measures in 1 randomised controlled trial.

The device is non‑invasive and non‑pharmaceutical.

No treatment‑related adverse events were identified.

The Airsonett device would be added to existing treatment and the average cost of long‑term treatment is £5.72 per day. The estimated cost of an add‑on therapy currently used in NHS practice, omalizumab, is £23 per day.

The device is used in the home to deliver cooled and filtered laminar airflow around the user's breathing zone (their nose and mouth). It is powered by domestic mains electricity.

The manufacturer provides both maintenance and consumables for the device.